TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7982869
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg per dose
Study: 7982869
Drug: Methylphenidate 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.6 mg/kg per dose
Study: 223601
Drug: calcium clofibrate
Normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: calcium clofibrate and calcium carbonate (4C, 2 + 2 g/day for 6 months)
Study: 223601
Drug: clofibrate (1C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: clofibrate (1C, 2 g/day for 6 months)
Study: 27836508
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus (L. rhamnosus) HN001 probiotic treatment for 4 weeks
Study: 26163236
Drug: Topical mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical mitomycin C (MMC)
Study: 21890526
Drug: Topiramate (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (daily use, titrated to maximum 200 mg/day for 3 months)
Study: 15047537
Drug: Quinine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine with primaquine at 15 mg/day
Study: 15047537
Drug: Quinine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine with primaquine at 30 mg/day
Study: 9564064
Drug: 0.5% intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% intraperitoneal subdiaphragmatic lidocaine 40 ml and 0.5% bupivacaine 5 ml infiltration of cannula insertion sites
Study: 21372034
Drug: SR13668 (38
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR13668 (38 mg oral dose)
Study: 19727884
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil capsules (340 mg EPA, 230 mg DPA, 450 mg DHA)
Study: 19727884
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (210 mg EPA, 30 mg DPA, 810 mg DHA)
Study: 19727884
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (containing sunola oil)
Study: 17387133
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg of reconstituted HDL (CSL‐111)
Study: 15114551
Drug: Pressure support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure support ventilation (PSV) with volume guarantee (VG) (Vt = 5 ml/kg) (n = 30)
Study: 11605121
Drug: Ipratropiumbromide inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropiumbromide inhalation with RC-Cornet(R)
Study: 11605121
Drug: Ipratropiumbromide inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropiumbromide inhalation with conventional inhalation (Pari-system)
Study: 2688737
Drug: Azathioprine 50
Normalized name: azathioprine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 50 mg t.d.s.
Study: 31741073
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of dexamethasone injected within 10 minutes of detected LOS in Group 2 (G2)
Study: 25114060
Drug: Autologous adipose-derived
Normalized name: Autologous adipose-derived stromal vascular fraction cells
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous adipose-derived stromal vascular fraction (SVF) injection
Study: 23569370
Drug: UMEC 500
Normalized name: Umecta
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMEC 500 μg/VI 25 μg
Study: 23569370
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg (administered on days 9-13)
Study: 19922877
Drug: Timolol gel-forming
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol gel-forming solution 0.5%
Study: 17124643
Drug: Hypericum extract
Normalized name: Hypericum extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypericum extract WS 5570 (900 mg/d or 1800 mg/d)
Study: 17124643
Drug: Paroxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (20 mg/d or 40 mg/d)
Study: 9643220
Drug: Tretinoin (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin (0.25 mg daily of 0.1% tretinoin cream)
Study: 2426902
Drug: Various established
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various established topical and systemic treatment regimes
Study: 16279889
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg combined with clarithromycin 500 mg and amoxicillin 1 g for 1 week
Study: 16279889
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg combined with clarithromycin 500 mg and amoxicillin 1 g for 1 week
Study: 12411798
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (50 mg/kg as a bolus, then 8 mg x kg(‐1) x h(‐1))
Study: 12411798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% sodium chloride solution)
Study: 12411798
Drug: Magnesium group
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium group (propofol infusion rate maintained at 80 microg x kg(‐1) x min(‐1))
Study: 12411798
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (propofol infusion rate maintained at 160 microg x kg(‐1) x min(‐1))
Study: 10470755
Drug: Traditional tidal
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional tidal volume ventilation (10-12 mL/kg ideal body weight)
Study: 10470755
Drug: Reduced tidal
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced tidal volume ventilation (5-8 mL/kg ideal body weight)
Study: 1283851
Drug: Vinorelbine (single-agent)
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (single-agent)
Study: 31335865
Drug: Decentralized Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decentralized Medication Delivery (DMD)
Study: 19945297
Drug: Intravenous remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous remifentanil (IV-R group, n = 13)
Study: 23344073
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Prostaglandin E2 (250-500 µg)
Study: 23344073
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of Prostaglandin E2 (250-500 µg)
Study: 12522370
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcipotriene 50 microg/g and betamethasone dipropionate 0.5 mg/g in the new vehicle
Study: 10917402
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous amitriptyline (150 mg/day)
Study: 10917402
Drug: Medium-dose intravenous
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose intravenous amitriptyline (100 mg/day)
Study: 10917402
Drug: Oral amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amitriptyline (150 mg/day)
Study: 2707124
Drug: bismuth subsalicylate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth subsalicylate, 1800 mg/d for four weeks
Study: 2707124
Drug: amoxycillin 2250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 2250 mg/d for two weeks
Study: 2707124
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg/d for four weeks
Study: 99226
Drug: Adjuvant MOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant MOPP chemotherapy combined with radiotherapy
Study: 99226
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy in chemotherapy management for stage IV patients
Study: 23200784
Drug: Attention Bias
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention Bias Modification Treatment (ABMT) training towards happy faces
Study: 23200784
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) only
Study: 21946915
Drug: Enoxaparin (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (prophylactic daily dose starting from the positive pregnancy test)
Study: 26352063
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dopamine treatment)
Study: 8730159
Drug: Basic compounds
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic compounds with high pKa (e.g., mecamylamine, pKa = 11.2)
Study: 8730159
Drug: Basic compounds
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic compounds with low pKa
Study: 8730159
Drug: Basic compounds
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic compounds with varying pKa
Study: 8730159
Drug: High pKa
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pKa compounds
Study: 8103470
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (HDM, n = 33)
Study: 8103470
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high dose metoclopramide (VHDM, n = 50)
Study: 8103470
Drug: Very high
Normalized name: Very high density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very high dose metoclopramide plus droperidol (VHDM+DP, n = 14)
Study: 29258678
Drug: CR (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR (daily calorie restriction)
Study: 24346753
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DXM) 360 mg/d for 7 days
Study: 24346753
Drug: Dextromethorphan (DXM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DXM) 360 mg/d
Study: 20211025
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ISG and ITP
Study: 12598260
Drug: droperidol 1
Normalized name: droperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 1 mg (dro-1 group; n = 20)
Study: 12598260
Drug: droperidol 2
Normalized name: droperidol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 2 mg (dro-2 group; n = 20)
Study: 10470576
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days, 0.125 mg/kg per day on the 7th day)
Study: 80682
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no steroid treatment)
Study: 8698957
Drug: Treatment participation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment participation
Study: 6336719
Drug: slow‐release metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: slow‐release metoprolol 200 mg once daily
Study: 30605458
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diclofenac and atropine
Study: 29792472
Drug: Baseline weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline weekly cannabis use
Study: 26507722
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil (AZL-M) 60 mg (3 × 20 mg capsules)
Study: 22874004
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text messages via mobile phone for 6 weeks
Study: 11466159
Drug: Investigational antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational antidepressants (venlafaxine ER and citalopram)
Study: 11466159
Drug: Investigational antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational antidepressants
Study: 26325387
Drug: ALB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALB treatment
Study: 24034304
Drug: FOS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS (5 g/day)
Study: 12752867
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group changed body position hourly (supine, right side-lying, left side-lying) for the first 7 hours after coronary angiography.
Study: 8417384
Drug: Deprenyl (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl (10 mg per day)
Study: 3530158
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg base once, followed by proguanil 100 mg per day
Study: 3530158
Drug: Iron 60
Normalized name: Iron 60mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron 60 mg daily
Study: 3530158
Drug: No active
Normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active treatment (Control group)
Study: 3530158
Drug: Proguanil (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proguanil (as part of the antimalarial regimen)
Study: 26615182
Drug: Clinical decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical decision support for renal dosage adjustments
Study: 17382150
Drug: Treatment recommendations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendations based on BOO classification
Study: 17382150
Drug: Treatment recommendations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment recommendations based on BOO probability
Study: 16333173
Drug: Viscoelastic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoelastic injection
Study: 16333173
Drug: No viscoelastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No viscoelastic injection
Study: 9445205
Drug: Pentoxifylline (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (400 mg 3 times a day orally, n=20)
Study: 92877
Drug: Aprotinin (Trasylol)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (Trasylol) administered intravenously
Study: 31422392
Drug: Desmopressin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin combined with 5 mg imipramine at bedtime
Study: 21233404
Drug: Tipifarnib and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib and bortezomib combination
Study: 31133061
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (0.3 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration
Study: 31133061
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of morphine (0.1 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration
Study: 2653041
Drug: Tocolysis, prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolysis, prophylactic antibiotics, and other interventions
Study: 31859246
Drug: CDKI plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDKI plus aromatase inhibitor
Study: 31859246
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aromatase inhibitor
Study: 25495101
Drug: Hypohydration (HYPO:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypohydration (HYPO: 200 ml water)
Study: 19001447
Drug: Structured therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured therapy interruption (STI)
Study: 16882745
Drug: Acyline (long‐acting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline (long‐acting GnRH‐antagonist) every 2 weeks
Study: 16882745
Drug: Acyline plus
Normalized name: Acyline
DrugBank: Acyline (DB11906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline plus testosterone (T) gel (10 mg/d)
Study: 8387176
Drug: Radiotherapy in
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy in combination with MIC
Study: 2450244
Drug: Nicardipine 30
Normalized name: niCARdipine 30 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 30 mg t.i.d. (three times a day)
Study: 29381241
Drug: incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: incisional negative pressure wound therapy (iNPWT)
Study: 27377115
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic agent plus low-power laser
Study: 27377115
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic agent (benzocaine)
Study: 25382325
Drug: Mizoribine (MZR)
Normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mizoribine (MZR) 300 mg every other day
Study: 25382325
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g per day in two divided doses
Study: 25382325
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CYC) 0.5 g every 2 weeks
Study: 25382325
Drug: Intravenous cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclophosphamide (CYC)
Study: 25382325
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) or Intravenous cyclophosphamide (CYC)
Study: 23548682
Drug: Reminiscing training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reminiscing training (four weekly in-home sessions in elaborative and emotion-rich reminiscing)
Study: 16809897
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of iron sucrose
Study: 28739539
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication review during hospital stay
Study: 28739539
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication review during hospital stay with active follow-up into primary care
Study: 25938655
Drug: Behavioral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral and nutritional treatment
Study: 25938655
Drug: Education and
Normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education and attention control treatment
Study: 23596814
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Traditional Chinese Medicine (TCM) and Western Medicine
Study: 23596814
Drug: Western Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western Medicine
Study: 18930251
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (200 mg eicosapentaenoic acid plus 1 g docosahexaenoic acid daily)
Study: 15113381
Drug: MonoRho (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MonoRho (300 micro g) intravenously
Study: 15113381
Drug: MonoRho (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MonoRho (300 micro g) intramuscularly
Study: 15113381
Drug: MonoRho (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: MonoRho (300 micro g) intravenously and intramuscularly
Study: 3666688
Drug: Corticosterone (CS)
Normalized name: 9alpha-fluoro-16alpha-methyl-delta(1)-corticosterone
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosterone (CS) treatment
Study: 22208409
Drug: Intermittent Preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent Preventive Treatment for malaria (IPTi)
Study: 19332196
Drug: Combination niacin-simvastatin
Normalized name: niacin / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination niacin-simvastatin (simvastatin 20 mg/Niacin-ER 2G)
Study: 19332196
Drug: Moderate-dose simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose simvastatin (20 mg)
Study: 11167173
Drug: Wiruthan bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wiruthan bronchial blocker (BB) - left mainstem bronchus (BBL)
Study: 11167173
Drug: Wiruthan bronchial
Normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Wiruthan bronchial blocker (BB) - right mainstem bronchus (BBR)
Study: 9429044
Drug: Thiopentone (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (9 mg.kg‐1 lean body mass)
Study: 26602699
Drug: Clonidine adhesive
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine adhesive patch
Study: 25715856
Drug: Conventional counselling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional counselling (CC)
Study: 23052644
Drug: Narrow-window sequential
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-window sequential CTCA
Study: 23052644
Drug: Wide-window sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide-window sequential CTCA
Study: 17536194
Drug: Fast-food meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-food meal (burger, French fries, root beer with high fructose corn syrup)
Study: 15180168
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT) for 12 weeks